STOCK TITAN

Enliven Therapeutics, Inc. - $ELVN STOCK NEWS

Welcome to our dedicated page for Enliven Therapeutics news (Ticker: $ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enliven Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enliven Therapeutics's position in the market.

Rhea-AI Summary
Enliven Therapeutics, Inc. (ELVN) announces positive proof of concept data from Phase 1 trial of ELVN-001 for chronic myeloid leukemia. ELVN-001 achieved a 44% MMR rate at 12 weeks in response-evaluable patients, showing promise in heavily pre-treated patients. The drug was well-tolerated with no Grade 3 toxicities reported. The company will host a virtual event with Key Opinion Leaders to discuss the data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.18%
Tags
-
Rhea-AI Summary
Enliven Therapeutics, Inc. appoints Dr. Lori Kunkel, a seasoned industry executive, to its Board of Directors. Dr. Kunkel brings extensive experience in oncology and immunology drug development. Enliven looks forward to her contributions as they progress with their lead product candidates, ELVN-001 and ELVN-002, through clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
management
-
Rhea-AI Summary
Enliven Therapeutics, Inc. (ELVN) will host a webcast to discuss initial proof of concept data on ELVN-001, a small molecule kinase inhibitor for chronic myeloid leukemia (CML). The event features leading CML investigators and management, highlighting the Phase 1a data and treatment paradigm in CML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.45%
Tags
Rhea-AI Summary
Enliven Therapeutics, Inc. announces a $90 million PIPE financing to support clinical programs for ELVN-001 and ELVN-002, extending cash runway into late 2026. The Company plans to host an event to discuss proof of concept data for ELVN-001 in adults with chronic myeloid leukemia. ELVN-002, a CNS penetrant HER2 inhibitor, shows promising results in combination with trastuzumab for HER2+ cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.77%
Tags
none
-
Rhea-AI Summary
Enliven Therapeutics, Inc. (ELVN) provided updates on their Phase 1a trial for ELVN-001 in chronic myeloid leukemia, FDA clearance for ELVN-002 in HER2+ cancers, and strong financial results for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
-
Rhea-AI Summary
Enliven Therapeutics, Inc. (ELVN) will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference. The company focuses on precision oncology and small molecule kinase inhibitors. The event will take place on March 5, 2024, at 12:50 p.m. ET and will be webcast live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
Rhea-AI Summary
Enliven Therapeutics, Inc. (ELVN) reports strong financial results for Q3 2023, with $263 million in cash and progress in Phase 1 trials for ELVN-001 and ELVN-002, expecting initial proof of concept data in 2024. The company also highlights the advancement of its early-stage pipeline and plans to provide additional guidance in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Enliven Therapeutics reports progress in Phase 1 trials and strong financial results for Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
Enliven Therapeutics, Inc.

Nasdaq:ELVN

ELVN Rankings

ELVN Stock Data

1.16B
19.55M
6.96%
81.01%
9.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOULDER

About ELVN

enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.